Immuneering (IMRX): Chief Business Officer received 140K units
Harold Eugene Brakewood, Chief Business Officer at Immuneering, reported a grant / award of 140K units.
- 140K
- Derivative units
- Traded
- Feb 3, 2026
- Filed
- Feb 5, 2026
The story around this disclosure
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.
- Jan 12, 2026InsiderDirector purchased ~$87K of IMRX shares in the open market
- Jan 13, 2026InsiderOfficer purchased ~$11K of IMRX shares in the open market
- Jan 15, 2026Insider · 2 peopleInsiders: 2 purchases (~$112K)
- Jan 16, 2026Insider · 5 insiders in a week, 4th time since 2021Officer purchased ~$25K of IMRX shares in the open market
What came next
How to read SEC Form 4
Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.
Full guide: What is an SEC Form 4?
What else is on file for Immuneering
For Immuneering, OQRO holds 1 insider filing (SEC Form 4 or Form 144) dated in the last 90 days.
These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its IMRX page.
Other recent filings by Harold Eugene Brakewood, Chief Business Officer
The full history of Harold Eugene Brakewood, Chief Business Officer is on the profile page.
How this filing works
Explore the data
Common questions
Which Immuneering (IMRX) insider traded, and how much?
Harold Eugene Brakewood, Chief Business Officer at Immuneering, reported a grant / award of 140K units. Not an open-market trade.
When did it happen, and when was it made public?
Traded: Feb 3, 2026. Filed: Feb 5, 2026. That is 2 days between the two dates.
Is the dollar amount exact?
It is the number of shares multiplied by the price the insider reported on the form. A grant, a gift or an option exercise has no market price, so those show shares only.
Where does this information come from?
From the SEC Form 4, a public record. The link to the official record is on this page, and OQRO copies its figures without changing them.
What else has been disclosed about Immuneering recently?
For Immuneering, OQRO holds 1 insider filing (SEC Form 4 or Form 144) dated in the last 90 days. They are listed on the IMRX page.
Does this mean IMRX stock is a buy or a sell?
No. This page describes one public filing. A filing does not say why someone traded and is not a forecast, so OQRO gives no recommendation.
Is OQRO free?
Yes. Every page of OQRO is free with an account, which takes a minute with Google and needs no card. Only the AI assistant is paid.
Other disclosures at Immuneering
- SEC Form 4Nov 16, 2026
- SEC Form 4Jun 24, 2026
- SEC Form 4Jun 16, 2026
- SEC Form 4Jan 21, 2026
- SEC Form 4Jan 20, 2026
- SEC Form 4Jan 16, 2026
Everything OQRO holds on this company is on its IMRX page.
This is one filing. OQRO holds the rest
Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.
OQRO is free for everyone. No card, no trial
OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data
